-
Trump says delaying Iran attack at request of Gulf leaders
-
Cuba warns of 'bloodbath' if US attacks and Washington issues sanctions
-
After mayor's murder, Mexico battles to bring peace
-
Trump admin creates $1.7 bln fund to compensate allies prosecuted under Biden
-
Pelicans name Mosley as coach, two weeks after Magic firing
-
Hyderabad qualify for IPL play-offs along with Gujarat
-
'Girl in the River Main' identified 25 years on, father arrested
-
Musk loses blockbuster OpenAI suit as jury says too late
-
SNC Scandic Coin and Biconomy: Regulated real-world assets meet global trading infrastructure
-
Judge allows gun as evidence in Mangione healthcare exec murder trial
-
First attack on Arab nuclear site sends warning to Gulf, US
-
Oil rises, bond yields weigh on stocks
-
Hormuz tanker traffic edges higher after wartime low
-
Andalusia setback highlights weakness of Spain's ruling Socialists
-
India's Adani to pay $275 mn settlement to US over alleged Iran sanctions violations
-
Middle East tourism pain is Europe's gain
-
UK Labour leadership hopeful reopens Brexit debate
-
PSG's Dembele has treatment for leg issue before Champions League final
-
Spurs must play with 'courage' to seal safety: De Zerbi
-
Hantavirus-hit cruise ship ends deadly voyage
-
Champagne start in Reims for 2028 Tour de France
-
Dogs allowed on new Brigitte Bardot beach in glitzy Cannes
-
Oil prices dip on report of US sanctions relief for Iran during talks
-
Croatia names Modric-led World Cup squad
-
Iran World Cup squad lands in south Turkey for training
-
Mushfiqur ton leaves Pakistan needing record run chase to beat Bangladesh
-
Transport protests hit Kenya over rising fuel prices
-
Ex-Google exec takes reins at under-fire BBC
-
France unveils architects to transform Louvre
-
'Mesmeric' movie on secret lives of Nigeria's rich wows Cannes
-
Ex-Google man takes reins at under-fire BBC
-
Swatch blames shopping centres for 'problems' with star product launch
-
Carvajal to leave Real Madrid at end of season
-
Stocks drop, oil climbs after fresh Trump warning to Iran
-
Blockbuster 'Hope' shows S.Korea's growing movie muscle
-
Twins wow Cannes with 'mesmeric' tale of Nigeria's rich
-
New Ebola outbreak in DR Congo: What we know
-
Iran Nobel winner discharged from hospital: supporters
-
Spanish court orders 55 mn euro tax refund to Shakira
-
Ryanair flags Iran war uncertainty as annual profit jumps
-
Hearts have bright future despite Scottish title pain: McInnes
-
Fernandes 'proud' to match Premier League assists record
-
Germany set to miss 2030 climate goal: experts
-
G7 finance chiefs meet to seek common stance on unstable ground
-
Freedom of speech 'not an absolute right', Hong Kong trial of Tiananmen activists hears
-
Hantavirus-hit cruise ship docks in Rotterdam at voyage end
-
Philippines swears in senators for VP Duterte's impeachment trial
-
Iran's World Cup football team leaves for Turkey: media
-
Hantavirus-hit cruise ship steams towards Rotterdam at voyage end
-
Japan arrests Americans over stunt at baby monkey Punch's zoo
RFK Jr panel votes against ingredient targeted by anti-vaxxers
A newly appointed US medical panel voted Thursday to oppose the use of a vaccine ingredient long targeted by Health Secretary Robert F. Kennedy Jr. over debunked claims it causes autism.
Thimerosal, a preservative that prevents bacterial and fungal contamination in multidose vials, has been extensively studied, with authorities including the World Health Organization finding no evidence of harm beyond minor injection-site reactions.
Though thimerosal is now rarely used in US vaccines, its inclusion on the Advisory Committee on Immunization Practices' agenda alarmed experts, who say the move has effectively embedded anti-vaccine talking points into national policy.
Kennedy -- who spent decades spreading vaccine misinformation before becoming President Donald Trump's top health official -- abruptly fired all 17 ACIP members earlier this month, accusing them of conflicts of interest.
Across three votes, his new handpicked panelists recommended that thimerosal be removed from influenza vaccines for children, pregnant women and finally all adults.
Cody Meissner, a professor of pediatrics at Dartmouth University and the lone voice of dissent, said: "The risk from influenza is so much greater than the nonexistent risk as far as we know from thimerosal," adding that he was worried about the decision's global impact.
Although 96 percent of US flu vaccines in the 2024-2025 season did not contain thimerosal, the preservative remains important globally, particularly in multidose vials that must be punctured repeatedly, raising the risk of contamination.
Thimerosal contains an artificial form of mercury called ethylmercury that is cleared from the body far more quickly than the form of the substance found in nature.
US manufacturers voluntarily removed it from most pediatric vaccines in 2001.
- 'Platform for anti-vaccine talking points' -
"The fact that it's being brought up again -- something that's already been adjudicated -- shows how the ACIP is becoming a platform for anti-vaccine talking points to come back to life long after most of us thought they'd been put to rest," Amesh Adalja, an infectious disease specialist at Johns Hopkins University, told AFP.
Ahead of the vote, Lyn Redwood, a nurse and former leader of the anti-vaccine group Children's Health Defense, which Kennedy once chaired, was invited to present arguments against thimerosal.
A previous version of her slideshow, which was posted online before the meeting, was removed without explanation after it was found to contain a fabricated citation, likely the result of an AI hallucination.
The Centers for Disease Control and Prevention had prepared a rebuttal to Redwood's presentation, but it was mysteriously removed from the meeting website.
Robert Malone, a new panel member known for spreading misinformation during the Covid-19 pandemic, including promoting the antiparastic drug ivermectin to treat the virus, later said the CDC document had not been approved by the Office of the Secretary.
Earlier in the meeting, the same panel voted to recommend a new antibody treatment against RSV, a common respiratory illness and the leading cause of infant hospitalization in the United States.
Clesrovimab, recently approved by the Food and Drug Administration, is administered as a single shot to newborns and young babies entering their first respiratory syncytial virus season.
Marketed as Enflonsia by Merck, it was shown in clinical trials to significantly reduce RSV infections and hospitalizations among infants.
O.Mousa--SF-PST